FGF21 and type 2 diabetes mellitus: Emerging clinical evidence demonstrates that elevated circulating FGF21 can be used as a biomarker of metabolic diseases such as metabolic dysfunction–associated steatohepatitis (MASH) and type 2 diabetes (23, 24).